« January 2008 | Main | March 2008 »
MED Institute move to mean more jobs Journal and Courier, IN - By MERANDA WATLING The move to new offices in the former Great Lakes Chemical Corp. building will allow biotechnology developer MED Institute to bring 120 ... |
 | Google Invests In DNA Sequencing Project TechCrunch, CA - The new investment takes Google further towards its quest to index any and everything on the planet, having invested in genetics testing company 23andme ... |
Researchers Uncover New Genetic Link To Lou Gehrig's Disease AHN - 28 online issue of Science, provide "a link between genetics and [the] pathology that proves that the pathology is important for the disease," said Virginia ... |
Applera & Celera Separation, For Real This Time (ABI, CRA) 24/7 Wall St., NY - Celera Genomics was formed in 1998 and in 1999 there was a recapitalization in a two-class stock issuance. In early 2000, a follow-on offering of Applera ... |
AUTM Panel: Platform Techs Best Bet for Deals Between Biopharma ... GenomeWeb News (subscription), NY - ... with Dana-Farber Cancer Institute to tackle cancer genomics; and with the H. Lee Moffitt Cancer Center in the area of personalized medicine. ... |
PerkinElmer Names Sullivan Director, Ullrich Wins Cancer Research ... GenomeWeb News (subscription), NY - Ullrich won the award for his work in the translation of genomics discoveries into cancer therapeutics approaches. Ullrich will receive a cash award of ... |
 | Cast a fresh eye on the menacing snake plant Providence Journal, RI - a Therea s nothing in the modern house their genetics havena t seena in the wild, McLaughlin said. I asked the pair to show me the range of snake plants at the ... |
Neurofibromatosis I Report advises on examination, anticipatory ... AAP News (subscription) - ... or when a couple seeks prenatal diagnosis of the condition. Dr. Hersh is lead author of the report and is a former member of the AAP Committee on Genetics. |
Scientists Unveil Map of Corn Genome Lancaster Farming, PA - A group of researchers led by Washington University in St. Louis have mapped out the corn planta s massive genome, and is posting the research on the ... |
EpiCept Corporation Q4 2007 Earnings Call Transcript Seeking Alpha, NY - We have also been pleased with the progress made by our partner Myriad Genetics with our licensed cancer compound Azixa. Myriad is currently conducting ... |
SANTA BARBARA, Calif., Feb. 29 /PRNewswire/ -- CNN's recent expose on asbestos in children's toys demonstrates the shocking reality that the deadly carcinogen is virtually everywhere in our environment. For decades, asbestos was used heavily in Navy ships and shipyards; in workplaces; in common building materials including drywalls, flooring, roofing materials, and cement pipes; in automotive products like brake pads; and even in common consumer products like hair dryers. As a result, the carcinogen has permeated our homes, offices and schools. The EPA estimates that one asbestos product alone -- a highly toxic "vermiculite" insulation -- is present today in 35 million U.S. homes. Tens of millions of Americans have already been exposed to asbestos, whether they knew it or not. Ten thousand Americans are now dying each year from past exposures that are too late to prevent. Deadly exposures will continue long into the future, because of all the asbestos already in our environment and the impossibility of remediating it. The tragedy of 9/11 demonstrates the continued, long-term threat. Estimates of the amount of asbestos released around Manhattan range as high as 1,000 tons. The impact pulverized the asbestos material into microscopic, easily respirable fibers to which the firefighters, rescue workers and other heroes were exposed. In the ensuing months, workers, residents and school children in the area continued to be exposed. For all those who are now sick, who have already been exposed and are at risk, or who will inevitably be exposed in the future, the only hope is research now to develop effective medical treatments. But research on the asbestos-cancer, mesothelioma, lags far behind other cancers. As a result of the limited treatment options, most mesothelioma patients die within one year of diagnosis. The Mesothelioma Applied Research Foundation (Meso Foundation) therefore is dedicated to promoting the research critically-needed to develop treatments for mesothelioma. As the nation's only independent, scientifically-based source of private mesothelioma research funding, The Meso Foundation has awarded over million in research grants to stellar projects around the world. Additionally, through The Meso Foundation's advocacy, research funding for asbestos-related diseases has been included in the "Bruce Vento Ban Asbestos and Prevent Mesothelioma Act" which is currently in the hands of Congress. A strong effort on the federal level is needed now to develop treatments for asbestos-cancer. Says, Meso Foundation Executive Director Chris Hahn, "We have accomplished a lot with limited, private funding. It is time for the federal government to partner with us in the search for a cure before more lives are lost." CONTACT: Joel Schnur for The Meso Foundation, 1-212-489-0600 Ext. 204,
or cell, 1-917-647-2249
Biotech Firm to Provide Ethical Alternatives to Aborted Fetal Vaccines Christian News Wire (press release), DC - 29 /Christian Newswire/ -- In a victory for pro-life families around the world, AVM Biotechnology LLC (AVM Biotech) today announced their decision to ... |
IRVINE, Calif., Feb. 29 /PRNewswire-FirstCall/ -- NuRx Pharmaceuticals Inc. The healthcare communications firm will implement a comprehensive program that consists of investor targeting, the scheduling of presentations at industry conferences, media relations and other corporate visibility initiatives. Russo Partners will collaborate with OTC Communications, a division of Rx Communications Group LLC, on the implementation of some program tactics. "We are in a unique position with a clinical-stage pipeline and large portfolio of retinoid and rexinoid compounds that were developed over a number of years by world-class researchers who have joined the NuRx scientific team," said Harin Padma-Nathan, M.D., NuRx's president and CEO. "We intend to initiate three to four clinical trials this year. Therefore, the need to support the associated news flow prompted us to select Russo Partners to develop and lead our communications efforts with Wall Street and the biotech/pharmaceuticals community. The firm has the healthcare industry expertise, senior-level talent and investor and media relationships that were critical to our selection of a communications partner." Russo Partners LLC, formerly Noonan Russo, provides strategic communications services to emerging healthcare - biotech, medical device, diagnostics and healthcare services - companies worldwide. Headquartered in New York City, the firm has a West Coast office in San Diego and an affiliated office in London. For more information, visit http://www.russopartnersllc.com/. NuRx Pharmaceuticals Inc. is an emerging biotech company focused on the development of retinoid and rexinoid compounds with application in oncology (treatment, prevention and adjunctive supportive therapy), the treatment of diabetes, the regulation of lipid metabolism and bone metabolism and repair. The company's lead compounds are (1) NRX4204, a highly specific, first-in-class rexinoid agonist that is targeted for development in non-small cell lung carcinoma and breast cancer; (2) NRX5183, a RAR alpha subtype- specific agonist for the treatment of acute leukemia; and (3) NRX4310, a function selective receptor modulator for the treatment and prevention of chemotherapy-induced neutropenia. Located in Irvine, Calif., NuRx has a technology and IP platform that includes a library of nearly 6,000 compounds supported by 230 issued U.S. and international patents and more than 80 additional patents in application. For more information, visit http://www.nurxpharmaceutical.com/. The above information contains information relating to the Company that is based on the beliefs of the Company and/or its management as well as assumptions made by and information currently available to the Company or its management. The Company, from time to time, may discuss forward-looking information. Except for the historical information contained in this news release, all forward-looking statements are predictions by the Company's management and are subject to various risks and uncertainties that may cause results to differ from management's current expectations. Such factors include the fact that the Company is engaged in early stage research and does not expect to obtain any revenues for several years and other risks as detailed from time to time in the Company's registration statement and reports and filings with the Securities and Exchange Commission. All forward-looking statements, if any, in this news release represent the Company's judgment as of the date of this news release. The Company disclaims, however, any intent or obligation to update forward-looking statements. CONTACTS: Media David Schull (212) 845-4271 CONTACT: Media: David Schull, 1-212-845-4271, Web site: http://www.nurxpharmaceutical.com/
1-917-322-2569,
http://www.russopartnersllc.com/
NCGA Joins Growers, Industry and NGOs to Create Agriculture ... Primenewswire (press release), CA - New technologies and better plant genetics have helped us increase yields and reduce trips over the field for tillage, weed and insect control. ... |
Rosetta Genomics Reports Fourth-Quarter and Full-Year 2007 ... Earthtimes, UK - "Rosetta Genomics had a truly remarkable year in 2007, with significant progress, in all fronts of our business, toward meeting patients' unmet medical ... |
ROCKVILLE, Md., Feb. 29 /PRNewswire-FirstCall/ -- A study reported in the journal Pharmacogenomics suggests that a genetic variation in the Ciliary Neurotrophic Factor gene (CNTF) may affect response to antipsychotic treatment. The study, conducted by Vanda Pharmaceuticals Inc., included patients with acute symptoms of schizophrenia who were treated either with Fiapta(TM) (iloperidone), a novel atypical antipsychotic agent currently under review with the FDA, or placebo. Patients were also studied for a genetic variation in the CNTF gene. CNTF is a neurotrophic factor important for neuronal survival and recovery after injury. About 75% of the population carry two intact copies of the CNTF protein while 25% carry one or two truncated copies of the protein. As previously reported in the clinical study overall, it was shown that Fiapta(TM) was significantly more effective than placebo in treating both the positive and negative symptoms of schizophrenia. In addition, Fiapta(TM) showed significant improvement from baseline in all symptoms across all patient genotypes of CNTF. In the patient population carrying both intact copies of CNTF (representing 75% of the population), Fiapta(TM) treatment was significantly better than placebo in symptom improvement. In patients carrying at least one truncated copy of the CNTF protein, placebo and Fiapta(TM) treated patients had a significant improvement from baseline indicating an enhanced placebo response among this group of patients. "This is a pioneering effort in understanding why some people respond to antipsychotic medication and others do not. The results of this prospective study on the genetics of drug response offer tantalizing clues on the involvement of neurotrophic factors in schizophrenia," said Steven G. Potkin, MD, Professor of Psychiatry, Robert R. Sprague Chair in Brain Imaging, and Director, Clinical Psychiatric Research at the University of California, Irvine. These findings suggest that neurotrophic factors like CNTF and genetic variations within them may play important roles in antipsychotic response and the course of illness of patients with schizophrenia. "This study is an important first step towards understanding the role of genetic variation in antipsychotic treatment response and eventually the introduction of personalized medicine in the treatment of schizophrenia," noted Dr. Anil Malholtra, MD, Director, Division of Psychiatry Research, The Zucker Hillside Hospital. About Vanda Pharmaceuticals Inc. Vanda Pharmaceuticals Inc. Note Regarding Forward-Looking Statements This release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding Vanda's plans for its product candidates. Words such as, but not limited to, "look forward to," "believe," "expect," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," "should," and "could," and similar expressions or words identify forward-looking statements. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Vanda is at an early stage of development and may not ever have any products that generate significant revenue. Important factors that could cause actual results to differ materially from those reflected in Vanda's forward-looking statements include, among others, a failure of Vanda's product candidates to be demonstrably safe and effective, a failure to obtain regulatory approval for the company's products or to comply with ongoing regulatory requirements, a lack of acceptance of Vanda's product candidates in the marketplace, a failure of the company to become or remain profitable, Vanda's inability to obtain the capital necessary to fund its research and development activities, a loss of any of the company's key scientists or management personnel, and other factors that are described in the "Risk Factors" section (Part II, Item 1A) of Vanda's report on Form 10-Q for the quarter ended September 30, 2007 (File No. 000-51863). No forward-looking statements can be guaranteed and actual results may differ materially from such statements. The information in this release is provided only as of the date of this release, and Vanda undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law. CONTACT: Media, Rachel Martins, Vice President of Ketchum, Web site: http://www.vandapharma.com/
1-646-935-4137,
or Steven Shallcross, Chief Financial Officer of Vanda Pharmaceuticals Inc.,
1-240-599-4537;
GERMANTOWN, Md., Feb. 29 /PRNewswire-FirstCall/ -- MiddleBrook Pharmaceuticals, Inc. Edward M. Rudnic, Ph.D., president and chief executive officer, will host a conference call to discuss the results and other corporate developments at 10:30 AM ET on Tuesday, March 4, 2008. Also participating on the call will be Robert C. Low, vice president, finance and CFO. To participate in the conference call, dial the appropriate number below shortly before the 10:30 AM start time and ask for the MiddleBrook Pharmaceuticals conference call hosted by Dr. Rudnic. The teleconference dial-in numbers are as follows: Domestic callers 1-800-813-8504 International callers 1-706-643-7752 The conference call will be broadcast simultaneously and archived on the Company's web site, http://www.middlebrookpharma.com/. Investors should go to the web site at least 15 minutes early to register, download, and install any necessary audio software. A replay of the call will be available on Tuesday, March 4, 2008, beginning at 12:30 PM ET and will be accessible until Tuesday, March 11, 2008, at 5:00 PM ET. The replay call-in number is 1-800-642-1687 for domestic callers and 1-706-645-9291 for international callers. The access number is 37507035. ABOUT MIDDLEBROOK PHARMACEUTICALS: MiddleBrook Pharmaceuticals, Inc. CONTACT: Bob Bannon, Vice President, Investor Relations & Corporate Web site: http://www.middlebrookpharma.com/
Communications, MiddleBrook Pharmaceuticals, Inc., 1-301-944-6710,
The SI Report: Market Review for Chemokine Therapeutics Corp. Trading Markets (press release), CA - Chemokine Therapeutics is a product-focused biotechnology company developing drug candidates in the field of chemokines. Chemokines are a class of signaling ... |
American Filtration and Separations Society to Hold 21st Annual ... Emediawire (press release), WA - The Conference will include 27 sessions divided into three tracks: Emerging Technologies; Fundamentals and Applications; and Biotechnology and ... |
Diatom research reveals possible climate solutions Daily - University of Washington, WA - Mock said scientists must dig deeper into the function of the diatoma s genetics. a At least 50 percent of these novel genes have no function at all,a he said ... |
Googlea s new health service gets a workout Siliconrepublic.com, Ireland - In May 2007, Google invested US.9m in 23andMe, an emerging biotechnology firm started by Anne Wojcicki, the wife of Google co-founder Sergy Brin. ... |
Appendix 4D Sydney Morning Herald, Australia - APPENDIX 4D HALF YEAR REPORT Proteome Systems Limited ACN 080 277 998 Current Reporting Period Half Year ended 31 December 2007 Previous corresponding ... |
BioInformatics, LLC Studies Trade Show Exhibition Strategies in ... Genetic Engineering News (press release), NY - 28 /PRNewswire/ -- BioInformatics, LLC (http://www.gene2drug.com) -- the leading market research and consulting firm serving the life science industry ... |
Workshop promotes education during eating disorder awareness week U.S. Marine Corps Bases Japan, Japan - "It can be unrealistic for some people based on their genetics." The average person sees approximately 3000 advertisements a day, a third of which contain ... |
 | House Passes Life Science Bill; 9.5M for MCLA iBerkshires.com, MA - ... 0 million to aid postdoctoral and graduate students studying life sciences, the establishment of new grant programs to boost the biotechnology work ... |
Oracle Unit Lobbied on Patents, Visas The Associated Press - Technology and financial services firms support the legislation, but pharmaceutical and biotechnology companies said it would weaken patent protection by ... |
 | Genesis Research burns .2m cash in 2007 Stuff.co.nz, New Zealand - Biotechnology company Genesis Research and Development is expecting "milestone achievements" this year following a net loss for the year to December of ... |
Genetic Screening Program Linked to Drop in CF Newborns MedPage Today, NJ - 28 -- The number of infants born with cystic fibrosis in Massachusetts decreased by 50% from one four-year period to the next, as a genetic screening ... |
Full Text Science Magazine (subscription) - Among those who should take note are doubters of "old-fashioned" research methods who marvel at the prospects of genomics in the lab and wonder what use ... |
SAN DIEGO, Feb. 28 /PRNewswire-FirstCall/ -- CryoCor, Inc. CryoCor's complaint covers three patents exclusively licensed to CryoCor in certain fields of use related to its Cardiac Cryoablation System, including patents covering pre-cooling technologies that CryoCor considers important to CryoCath's cryoablation system. This action is independent of a patent interference that has been declared by the United States Patent and Trademark Office between CryoCor and CryoCath, where CryoCor has been declared the senior party. If the ITC accepts the complaint, it will institute a formal Section 337 investigation within 30 days. Section 337 investigations are completed on a fast track, typically within 15 months of the submission of the complaint. If the ITC determines that CryoCath's cryoablation system infringes on CryoCor's licensed patents and that CryoCath's products are being imported into the United States, the ITC may order that CryoCath's cryoablation system, and associated catheters and parts, be completely excluded from importation into the U.S. market for the life of the patents. ITC exclusion orders are enforced by the U.S. Customs and Border Protection. Ed Brennan, Ph.D., President and Chief Executive Officer of CryoCor, said, "Our request for this investigation further reinforces our strategy to protect our intellectual property rights. Importantly, an ITC investigation has a fast timeline for completion, usually just over one year. If we prevail, the ITC may issue a ban on importation of CryoCath's cryoablation system into the United States. We expect to hear from the ITC within 30 days and will provide an update upon their response. We are confident in the strength of our patent portfolio and believe that we have a solid position as a technological leader in cardiac cryoablation." About CryoCor CryoCor is a medical technology company that has developed and manufactures a disposable catheter system based on its proprietary cryoablation technology for the minimally invasive treatment of cardiac arrhythmias. The Company's product, the CryoCor Cardiac Cryoablation System, or the Cryoablation System, is designed to treat cardiac arrhythmias through the use of cryoenergy, or extreme cold, to destroy targeted cardiac tissue. The Cryoablation System has been approved in Europe for the treatment of atrial fibrillation, and atrial flutter, the two most common and difficult to treat arrhythmias, since 2002. In the United States, CryoCor is conducting a pivotal trial to evaluate the safety and efficacy of the Cryoablation System for the treatment of atrial fibrillation and the Cryoablation System has been approved for the treatment of right atrial flutter. For more information please visit the Company's website at http://www.cryocor.com/ Forward Looking Statements The statements in this press release that are not descriptions of historical facts are forward-looking statements that are subject to risks and uncertainties. These include statements related to whether the ITC will accept CryoCor's complaint, the possible remedies that may be imposed against CryoCath by the ITC, the merits of CryoCor's positions in the ITC proceedings with CryoCath, the possible outcome of those proceedings, and the value of pre-cooling technology in a cryoablation system, and specifically, CryoCath's cryoablation system, all of which are prospective. Such statements are only predictions and reflect CryoCor's expectations and assumptions as of the date of this press release based on currently available operating, financial, and competitive information. The actual events or results may differ materially from those projected in such forward-looking statements due to a number of factors, including risks involved with CryoCor's technology; risks associated with the Company's dependence on patents and proprietary rights; risks associated with the Company's protection and enforcement of its patents and proprietary rights; risks associated with the development or availability of competitive products or technologies and the other risks and uncertainties identified in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company expressly disclaims any intent or obligation to update any of these forward-looking statements. CryoCor, Inc. The Ruth Group Gregory J. Tibbitts Nick Laudico / Zack Kubow (investors) Chief Financial Officer (646) 536-7030 / 7020 (858) 909-2200 CONTACT: Gregory J. Tibbitts, Chief Financial Officer of CryoCor, Inc., Web site: http://www.cryocor.com/
1-858-909-2200,
1-646-536-7030,
